Mydrilate (Cyclopentolate Hydrochloride Bp)

Cyclopentolate hydrochloride blocks muscarinic acetylcholine receptors in the iris sphincter and ciliary body. This antagonism prevents parasympathetic stimulation, leading to relaxation of the sphincter muscle and ciliary muscle, which results in pupil dilation and loss of accommodation.

The dosing regimen for Mydrilate is determined by the prescribing eye care professional based on the specific clinical need, patient age, and ocular condition. No standard dose is provided here; the prescriber sets the appropriate number of drops and frequency.

Safety data for cyclopentolate hydrochloride in pregnancy and lactation are limited. The product is classified as having an unknown pregnancy category, so it should be used only if the potential benefit justifies any potential risk to the fetus or infant, and under medical supervision.

To order Mydrilate, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both Mydrilate (cyclopentolate) and phenylephrine are mydriatic agents, but they act on different pathways. Cyclopentolate blocks muscarinic receptors, producing both dilation and cycloplegia, whereas phenylephrine stimulates adrenergic receptors, causing dilation without affecting accommodation. Choice depends on the clinical requirement for cycloplegia.

Mydrilate should be stored at room temperature, below 25 °C, in its original container. Protect the solution from direct light and moisture. Keep the bottle tightly closed when not in use and discard any product that appears discolored or contaminated.

Mydrilate is applied topically to the eye as an ophthalmic solution. The prescribed number of drops is instilled into the conjunctival sac of the target eye(s) using a sterile dropper. Administration is performed by a qualified eye‑care professional or as instructed by the prescriber.

The most serious adverse events include acute angle‑closure glaucoma, severe allergic reactions such as angio‑edema or anaphylaxis, and systemic anticholinergic toxicity presenting as dry mouth, rapid heart rate, confusion, or urinary retention. Immediate medical attention is required if any of these occur.

Mydrilate should be avoided in patients with known hypersensitivity to cyclopentolate or other anticholinergic agents, in individuals with narrow‑angle or uncontrolled glaucoma, and in those where significant systemic anticholinergic effects could be hazardous, such as certain elderly patients or those with severe cardiac disease.